Mechanism of Paroxetine (Paxil) Inhibition of the Serotonin Transporter

被引:0
|
作者
Bruce A. Davis
Anu Nagarajan
Lucy R. Forrest
Satinder K. Singh
机构
[1] Yale University School of Medicine,Department of Cellular and Molecular Physiology
[2] Computational Structural Biology Section,undefined
[3] National Institute of Neurological Disorders and Stroke,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The serotonin transporter (SERT) is an integral membrane protein that exploits preexisting sodium-, chloride- and potassium ion gradients to catalyze the thermodynamically unfavorable movement of synaptic serotonin into the presynaptic neuron. SERT has garnered significant clinical attention partly because it is the target of multiple psychoactive agents, including the antidepressant paroxetine (Paxil), the most potent selective serotonin reuptake inhibitor known. However, the binding site and orientation of paroxetine in SERT remain controversial. To provide molecular insight, we constructed SERT homology models based on the Drosophila melanogaster dopamine transporter and docked paroxetine to these models. We tested the predicted binding configurations with a combination of radioligand binding and flux assays on wild-type and mutant SERTs. Our data suggest that the orientation of paroxetine, specifically its fluorophenyl ring, in SERT’s substrate binding site directly depends on this pocket’s charge distribution and thereby provide an avenue toward understanding and enhancing high-affinity antidepressant activity.
引用
收藏
相关论文
共 50 条
  • [1] Mechanism of Paroxetine (Paxil) Inhibition of the Serotonin Transporter
    Davis, Bruce A.
    Nagarajan, Anu
    Forrest, Lucy R.
    Singh, Satinder K.
    SCIENTIFIC REPORTS, 2016, 6
  • [2] A mechanism of uncompetitive inhibition of the serotonin transporter
    Bhat, Shreyas
    El-Kasaby, Ali
    Kasture, Ameya
    Boytsov, Danila
    Reichelt, Julian B.
    Hummel, Thomas
    Sucic, Sonja
    Pifl, Christian
    Freissmuth, Michael
    Sandtner, Walter
    ELIFE, 2023, 12
  • [3] Paroxetine (Paxil) and congenital malformations
    Williams, M
    Wooltorton, E
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2005, 173 (11) : 1320 - 1321
  • [4] Estimates of Serotonin and Norepinephrine Transporter Inhibition in Depressed Patients Treated with Paroxetine or Venlafaxine
    Michael J Owens
    Stan Krulewicz
    Jeffrey S Simon
    David V Sheehan
    Michael E Thase
    David J Carpenter
    Susan J Plott
    Charles B Nemeroff
    Neuropsychopharmacology, 2008, 33 : 3201 - 3212
  • [5] Estimates of Serotonin and Norepinephrine Transporter Inhibition in Depressed Patients Treated with Paroxetine or Venlafaxine
    Owens, Michael J.
    Krulewicz, Stan
    Simon, Jeffrey S.
    Sheehan, David V.
    Thase, Michael E.
    Carpenter, David J.
    Plott, Susan J.
    Nemeroff, Charles B.
    NEUROPSYCHOPHARMACOLOGY, 2008, 33 (13) : 3201 - 3212
  • [6] Paroxetine (Paxil) overdose: A pediatric focus
    Myers, LB
    Krenzelok, EP
    VETERINARY AND HUMAN TOXICOLOGY, 1997, 39 (02) : 86 - 88
  • [7] Occupancy of the serotonin transporter by paroxetine or citalopram during treatment of depression
    Meyer, JH
    Wilson, AA
    Ginovart, N
    Goulding, V
    Hood, K
    Hussey, D
    Houle, S
    BIOLOGICAL PSYCHIATRY, 2001, 49 (08) : 118S - 118S
  • [8] Molecular Mechanism for the Allosteric Inhibition of the Human Serotonin Transporter by Antidepressant Escitalopram
    Xue, Weiwei
    Fu, Tingting
    Deng, Shengzhe
    Yang, Fengyuan
    Yang, Jingyi
    Zhu, Feng
    ACS CHEMICAL NEUROSCIENCE, 2022, 13 (03): : 340 - 351
  • [9] Platelet serotonin uptake and paroxetine binding among allelic genotypes of the serotonin transporter in alcoholics
    Javors, MA
    Seneviratne, C
    Roache, JD
    Ait-Daoud, N
    Bergeson, SE
    Walss-Bass, MC
    Akhtar, FZ
    Johnson, BA
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2005, 29 (01): : 7 - 13
  • [10] Antipanic efficacy of paroxetine and polymorphism within the promoter of the serotonin transporter gene
    Perna, G
    Favaron, E
    Di Bella, D
    Bussi, R
    Bellodi, L
    NEUROPSYCHOPHARMACOLOGY, 2005, 30 (12) : 2230 - 2235